Table Of Contents
1 Introduction 32
1.1 Overview Of Europe Injectable Drug Delivery Market 32
1.2 Currency And Pricing 33
1.3 Limitation 33
1.4 Markets Covered 34
2 Market Segmentation 37
2.1 Markets Covered 37
2.2 Geographic Scope 38
2.3 Years Considered For The Study 39
2.4 Currency And Pricing 39
2.5 Research Methodology 40
2.6 Primary Interviews With Key Opinion Leaders 43
2.7 Secondary Sources 44
2.8 Assumptions 44
3 Market Overview 45
3.1 Drivers 47
3.1.1 Rising Cases Of Chronic Diseases 47
3.1.2 Rising Demand Of Self-Injection Devices 49
3.1.3 Growth Of Biologics Market 49
3.1.4 Technological Advancements And Innovations In Drug Delivery Market 50
3.2 Restraints 51
3.2.1 Needlestick Injuries And Infections 51
3.2.2 High Cost Of Development 52
3.2.3 Strict Regulatory Framework 53
3.3 Opportunity 54
3.3.1 Increasing Demand For Generic And Biosimilar Drugs 54
3.3.1.1 Generics 54
3.3.1.2 Biosimilars 54
3.3.2 Increasing Demand For Contraceptive Injectables 55
3.3.3 Increasing Demand For Self-Administration Of Drugs 56
3.4 Challenges 57
3.4.1 Alternative Route Of Drug Administration 57
3.4.2 Product Recall 58
3.4.3 Stability Of Products 58
3.4.4 Sterility Of Injections 59
4 Executive Summary 60
5 Premium Insights 62
6 Europe Injectable Drug Delivery Market, By Type 65
6.1 Overview 66
6.2 Injectable Drug Delivery Devices 67
6.2.1 Conventional Injection Devices 68
6.2.1.1 Conventional Injection Devices, By Material 70
6.2.1.1.1 Glass 70
6.2.1.1.2 Plastic 70
6.2.1.2 Conventional Injection Devices, By Product 71
6.2.1.2.1 Fillable Syringes 71
6.2.1.2.2 Prefilled Syringes 72
6.2.1.3 Conventional Injection Devices, By Usability 73
6.2.1.3.1 Reusable Syringes 73
6.2.1.3.2 Disposable Syringes 73
6.2.2 Self Injection Devices 74
6.2.2.1 Needle Free Injectors (Nfi) 75
6.2.2.2 Needle Free Injectors, By Product 76
6.2.2.2.1 Fillable Needle-Free Injectors 76
6.2.2.2.2 Prefilled Needle-Free Injectors 76
6.2.2.3 Needle Free Injectors, By Technology 77
6.2.2.3.1 Jet Based Needle Free Injectors; 77
6.2.2.3.2 Spring Based Needle Free Injectors; 78
6.2.2.3.3 Laser Based Needle Free Injectors; 78
6.2.2.3.4 Vibration Based Needle Free Injectors; 78
6.2.2.4 Needle Free Injectors, By Usability 79
6.2.2.4.1 Reusable Needle-Free Injectors 79
6.2.2.4.2 Disposable Needle-Free Injectors 79
6.2.2.5 Auto Injectors 80
6.2.2.6 Auto Injectors, By Product 81
6.2.2.6.1 Fillable Auto Injectors 81
6.2.2.6.2 Pre-Filled Autoinjectors 81
6.2.2.7 Auto Injectors, By Technology 82
6.2.2.7.1 Automated Auto Injectors 82
6.2.2.7.2 Manual Auto Injectors 82
6.2.2.8 Auto Injectors, By Design 84
6.2.2.8.1 Standardized Auto Injectors 84
6.2.2.8.2 Automated Autoinjectors 84
6.2.2.9 Auto Injectors, By Usability 85
6.2.2.9.1 Reusable Autoinjectors 85
6.2.2.9.2 Disposable Autoinjectors 85
6.2.2.10 Pen Injectors 86
6.2.2.11 Pen Injectors, By Product 86
6.2.2.11.1 Single Chambered Pen Injectors 86
6.2.2.11.2 Dual Chambered Pen Injectors 87
6.2.2.12 Pen Injectors, By Design 87
6.2.2.12.1 Standard Pen Injectors 87
6.2.2.12.2 Customized Pen Injectors 88
6.2.2.13 Pen Injectors, By Usability 88
6.2.2.13.1 Reusable Pen Injectors 88
6.2.2.13.2 Disposable Pen Injectors 89
6.2.2.14 Wearable Injectors 89
6.2.2.14.1 Other Devices 90
6.3 Injectable Drug Delivery Formulation 91
6.3.1 Conventional Drug Delivery Formulations 92
6.3.1.1 Solutions 92
6.3.1.2 Reconstituted/Lyophilized Formulations 92
6.3.1.3 Suspensions 93
6.3.1.4 Emulsions 94
6.3.2 Novel Drug Delivery Formulations 96
6.3.2.1 Colloidal Dispersions 97
6.3.2.1.1 Niosomes 97
6.3.2.1.2 Liposomes 98
6.3.2.1.3 Polymeric Mixed Micelles 99
6.3.2.1.4 Nanoparticles 100
6.3.2.1.5 Nanosuspensions 100
6.3.2.1.6 Nanoemulsions/Microemulsions 101
6.3.2.1.7 Solid Lipid Nanoparticles 102
6.3.2.2 Microparticles 103
6.3.2.2.1 Microspheres 103
6.3.2.2.2 Microcapsules 104
6.3.2.3 Long Acting Injection Formulation 105
7 Europe Injectable Drug Delivery Market, By Application 107
7.1 Overview 108
7.2 Europe Injectable Drug Delivery Market, By Application 109
7.3 Hormonal Disorders 110
7.3.1 Injectable Drugs For Diabetes 110
7.3.2 Injectable Drugs For Anemia 111
7.3.3 Injectable Drugs For Reproductive Health Disease 113
7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy 114
7.3.5 Injectable Drugs For Osteoporosis 114
7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd) 115
7.4 Oncology 117
7.5 Autoimmune Diseases 119
7.5.1 Injectable Drugs For Rheumatoid Arthritis 119
7.5.2 Injectable Drugs For Multiple Sclerosis 120
7.5.3 Injectable Drugs For Crohn?S Diseases 121
7.5.4 Injectable Drugs For Psoriasis 122
7.5.5 Injectable Drugs For Other Autoimmune Diseases 123
7.6 Orphan Disease 124
7.7 Other Applications 126
7.7.1 Injectable Drugs For Pain Management 126
7.7.2 Injectable Drugs For Allergy Treatment 127
7.7.3 Injectable Drugs For Aesthetic Treatments 128
7.7.4 Injectable Drugs For Hepatitis C 129
7.7.5 Injectable Drugs For Hemophilia 130
8 Europe Injectable Drug Delivery Market, By Usage Pattern 132
8.1 Overview 133
8.2 Curative Care 134
8.3 Immunizations 135
8.4 Other Usage Pattern 136
9 Europe Injectable Drug Delivery Market, By Mode Of Administration 137
9.1 Overview 138
9.2 Skin 139
9.3 Circulatory/ Muskoskeletal 139
9.4 Organs 140
9.5 Central Nervous System 141
10 Europe Injectable Drug Delivery Market, By End User 142
10.1 Overview 143
10.2 Hospitals And Clinics 145
10.3 Home Healthcare Settings 145
10.4 Research Laboratories 145
10.5 Pharmaceutical And Biotechnological Companies 146
10.6 Other End Users 147
11 Europe Injectable Drug Delivery Market, By Distribution Channel 148
11.1 Overview 149
11.1.1 Hospital Pharmacy 150
11.1.2 Pharmacy Stores 150
11.1.3 Direct Tender 150
11.1.4 Online Pharmacy 150
12 Europe Injectable Drug Dilivery Market By Geography 152
12.1 Europe Injectable Drug Delivery Market 152
12.1.1 Germany Injectable Drug Delivery Market 170
12.1.2 France Injectable Drug Delivery Market 186
12.1.3 Uk Injectable Drug Delivery Market 202
12.1.4 Italy Injectable Drug Delivery Market 218
12.1.5 Switzerland Injectable Drug Delivery Market 234
12.1.6 Spain Injectable Drug Delivery Market 250
12.1.7 Netherland Injectable Drug Delivery Market 266
12.1.8 Russia Injectable Drug Delivery Market 283
12.1.9 Turkey Injectable Drug Delivery Market 298
12.1.10 Belgium Injectable Drug Delivery Market 313
12.1.11 Rest Of Europe Injectable Drug Delivery Market 329
13 Europe Injectable Drug Delivery Market, Company Share 330
13.1 Company Share Analysis; Europe 330
14 Company Profiles 331
14.1 Becton, Dickinson And Company 331
14.1.1 Company Overview 331
14.1.1.1 Drivers Explained 332
14.1.1.2 Weaknesses Explained 332
14.1.1.3 Oppurtunities Explained 333
14.1.1.4 Threats Explained 333
14.1.2 Product Portfolio 334
14.1.3 Recent Developments 335
14.2 Pfizer 336
14.2.1 Company Overview 336
14.2.1.1 Drivers Explained 337
14.2.1.2 Weaknesses Explained 338
14.2.1.3 Oppurtunities Explained 338
14.2.1.4 Threats Explained 339
14.2.2 Product Portfolio 340
14.2.3 Recent Developments 341
14.3 Baxter International 342
14.3.1 Company Overview 342
14.3.1.1 Drivers Explained 343
14.3.1.2 Weaknesses Explained 344
14.3.1.3 Oppurtunities Explained 344
14.3.1.4 Threats Explained 345
14.3.2 Product Portfolio 346
14.3.3 Recent Developments 347
14.4 Gerresheimer Ag 348
14.4.1 Company Overview 348
14.4.2 Product Portfolio 349
14.4.3 Recent Developments 349
14.5 Schott Ag Inc. 350
14.5.1 Company Overview 350
14.5.2 Product Portfolio 351
14.5.3 Recent Developments 351
14.6 Alkermes Inc. 352
14.6.1 Company Overview 352
14.6.2 Product Portfolio 353
14.6.3 Recent Developments 353
14.7 Antares Pharma 354
14.7.1 Company Overview 354
14.7.2 Product Portfolio 355
14.7.3 Recent Developments 355
14.8 Bespak (Subsidiary Of Consort Medical Company) 357
14.8.1 Company Overview 357
14.8.2 Product Portfolio 358
14.8.3 Recent Developments 358
14.9 Elcam Medical 359
14.9.1 Company Overview 359
14.9.2 Product Portfolio 359
14.9.3 Recent Developments 359
14.10 Eli Lilly And Company 360
14.10.1 Company Overview 360
14.10.1.1 Drivers Explained 361
14.10.1.2 Weaknesses Explained 362
14.10.1.3 Oppurtunities Explained 362
14.10.1.4 Threats Explained 363
14.10.2 Product Portfolio 364
14.10.3 Recent Developments 365
14.11 Haselmeier 366
14.11.1 Company Overview 366
14.11.2 Product Portfolio 366
14.11.3 Recent Developments 367
14.12 Mylan N.V. 368
14.12.1 Company Overview 368
14.12.2 Product Portfolio 368
14.12.3 Recent Developments 369
14.13 Novo Nordisk 370
14.13.1 Company Overview 370
14.13.2 Product Portfolio 371
14.13.3 Recent Developments 372
14.14 Owen Mumford Ltd 373
14.14.1 Company Overview 373
14.14.2 Product Portfolio 374
14.14.3 Recent Developments 374
14.15 Sandoz International Gmbh 375
14.15.1 Company Overview 375
14.15.2 Product Portfolio 376
14.15.3 Recent Developments 376
14.16 Sanofi 377
14.16.1 Company Overview 377
14.16.2 Product Portfolio 378
14.16.3 Recent Developments 379
14.17 Terumo Corporation 380
14.17.1 Company Overview 380
14.17.2 Product Portfolio 381
14.17.3 Recent Developments 381
14.18 Teva Pharmaceutical 383
14.18.1 Company Overview 383
14.18.1.1 Drivers Explained 384
14.18.1.2 Weaknesses Explained 384
14.18.1.3 Oppurtunities Explained 385
14.18.1.4 Threats Explained 386
14.18.2 Product Portfolio 387
14.18.3 Recent Developments 388
14.19 West Pharmaceutical Services, Inc 389
14.19.1 Company Overview 389
14.19.2 Product Portfolio 390
14.19.3 Recent Developments 391
14.20 Ypsomed Holding Ag 392
14.20.1 Company Overview 392
14.20.2 Product Portfolio 393
14.20.3 Recent Developments 393
15 Related Reports 394
?